Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Oral blarcamesine delivers long-term benefit in early AD
24 Oct 2025
bởiAudrey Abella
Findings from the phase IIb/III ATTENTION-AD study reflect the continued benefit of oral blarcamesine in individuals with early Alzheimer’s disease (AD) after receiving the drug continuously for up to 4 years.
24 Oct 2025

Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo
22 Oct 2025
bởiStephen Padilla
Treatment with the Janus kinase (JAK) 1 inhibitor povorcitinib results in significant repigmentation of the body and face in adult patients with extensive nonsegmental vitiligo (NSV), with an acceptable safety profile, through 52 weeks, reports a phase II study.
22 Oct 2025







